Pharmaceutical company, Gilead Sciences Inc., seeks to recoup over $4 million in legal fees accumulated by Usama Malik, the former chief financial officer of Immunomedics, a unit within Gilead. This repayment is associated with the legal cost that ensued during a federal investigation into alleged insider trading.
Usama Malik, 48, was serving as the CFO of the company when Gilead purchased Immunomedics for $21 billion back in 2020. Malik admitted guilt to criminal charges, confessing that he had tipped his girlfriend about a successful clinical trial concerning a breast cancer drug within minutes of obtaining the information himself. This enabled his girlfriend to yield more than $200,000 from stock sales. Consequently, Malik faced a six-month home arrest sentence and incurred a hefty $15,000 fine.
The underlying details are captured in a detailed report by Bloomberg Law. The linked article provides a much more comprehensive account of the case at hand, including a deep dive into the legal aspects surrounding the actions of Malik during his tenure at Gilead.
Interested readers can access the full coverage on this topic here
.